PROTAC-FAK

PROTAC-FAK (focal adhesion kinase proteolysis-targeting chimera) is a class of targeted protein degraders designed to selectively bind and induce the ubiquitination and subsequent proteasomal degradation of focal adhesion kinase (FAK, also known as PTK2). Unlike traditional small-molecule FAK inhibitors that only block its kinase activity, FAK PROTACs eliminate the entire FAK protein, thereby simultaneously disrupting both its enzymatic kinase-dependent signaling and its kinase-independent scaffolding functions. In preclinical studies of gastrointestinal neuroendocrine tumors (GI-NETs), the specific FAK PROTAC BI-0319 (developed by Boehringer Ingelheim) has been shown to overcome drug resistance, reduce cell viability, and inhibit tumor cell proliferation, migration, and invasion.

Other names

FAK PROTACFAK degraderfocal adhesion kinase PROTACproteolysis-targeting chimera-based FAK degraderPTK2 PROTACPTK-2 PROTACPTK 2 PROTAC